Skip to main content

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 22 05 2026] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Advantive Acquires Insequence, Strengthening Its Leadership in Automotive Manufacturing and Supply Chain Software

Tampa, May 26, 2026 (GLOBE NEWSWIRE) — Advantive, a provider of mission-critical software for specialty manufacturing and distribution businesses, today announced its acquisition of Insequence, a leading provider of automotive sequencing and manufacturing execution system (MES) software headquartered in Smyrna, Tennessee. Automotive manufacturers and suppliers are navigating increasing production complexity, evolving OEM requirements, and ongoing supply chain volatility. In this environment, real-time sequencing accuracy, plant floor visibility, and AI-driven production intelligence have become critical to operational success.  Insequence has been at the forefront of just-in-sequence (JIS) and MES innovation for three decades, enabling automotive suppliers to synchronize production, optimize inventory, and meet stringent delivery...

Continue reading

All In FutureTech Alliance Inc. Announces Filing of Form 8-K for HyalRoute Acquisition Transaction and Releases HyalRoute Business Overview and Financial Data

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) — All In FutureTech Alliance Inc. (Nasdaq: AGAE) (“AIFA” or the “Company”) today announced that it has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) relating to the Company’s previously announced transaction to acquire HyalRoute Fiber Optic Group (“HyalRoute”) at a price of US$10.00 per share. As part of the filing, the Company also released supplemental information provided by the transaction seller regarding HyalRoute’s business operations, infrastructure assets, strategic positioning, and projected financial performance. Details of the materials are set forth below: Overview of HyalRoute Group and Financial Outlook HyalRoute Communication Group Limited is a leading fiber-optic network and digital infrastructure company in ASEAN, founded...

Continue reading

TeraWulf Expands Infrastructure Platform with Acquisition of 1+ GW Eastern Kentucky HPC Campus

New “Muskie Data Campus” establishes one of the largest scalable AI and HPC development sites in Kentucky EASTON, Md., May 26, 2026 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), which owns and operates vertically integrated, next-generation digital infrastructure, today announced the acquisition of a hyperscale high-performance computing (“HPC”) development site strategically located in Eastern Kentucky (the “Muskie Data Campus”). The acquisition meaningfully expands TeraWulf’s portfolio of large-scale, energy-advantaged digital infrastructure campuses and advances the Company’s strategy of developing shovel-ready AI and HPC sites with long-term power availability, robust transmission infrastructure, and strong community alignment. The Muskie Data Campus, acquired from Industrial Equity Partners...

Continue reading

Schouw & Co. share buy-back programme, week 21 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount DKK    Accumulated until 15 May 2026 131,283 667.28 87,603,049    Monday, 18 May 2026 1,000 676.50 676,500    Tuesday, 19 May 2026 1,000 675.50 675,500    Wednesday, 20 May 2026 1,000 669.00 669,000    Thursday, 21 May 2026 1,000 684.00 684,000    Friday,...

Continue reading

Global-e to Enhance Logistics Offering with Acquisition of Passport, a US-based e-Commerce Logistics and Solutions Company

Acquisition expected to deepen Global-e’s standard logistics capabilities and improve the post-purchase experience for merchants and shoppersAcquisition focuses on asset-light carrier capabilities and offering of competitive best in class cross-border, domestic and “last mile delivery” standard logistics, supporting sophisticated solutions such as direct injection, consolidated returns and customs brokerageWill enable expansion of global offering to merchant segments that require a Non-Merchant of Record solution, leveraging the existing Passport platformPETAH-TIKVA, Israel, May 26, 2026 (GLOBE NEWSWIRE) — Global-e Online Ltd. (NASDAQ: GLBE) (“Global-e” or the “Company”), the platform powering global direct-to-consumer e-commerce, today announced that it has entered into a definitive agreement (the “Agreement”) to acquire...

Continue reading

Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention

Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products SEATTLE, May 26, 2026 (GLOBE NEWSWIRE) — Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive agreement to be acquired by Lilly. Curevo’s lead product candidate is amezosvatein, an adjuvanted subunit vaccine for the prevention of shingles in adults. While the current standard of care for shingles prevention is effective, tolerability challenges can limit the overall vaccination rates and contribute to second-dose hesitancy, leaving a meaningful portion of patients with reduced or no protection against shingles and its...

Continue reading

G2 Goldfields Announces Filing and Mailing of Meeting Materials in Connection With the Acquisition by G Mining Ventures and Spin-Out With G3 Goldfields

TORONTO, May 25, 2026 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company”) (TSX:GTWO; OTCQX:GUYGF) is pleased to announce that it has filed the management information circular (the “Circular”) and related meeting materials (collectively, the “Meeting Materials”) for the special meeting of the holders of common shares of G2 (the “G2 Shareholders”) to be held on June 16, 2026 (the “Meeting”). The mailing of the Meeting Materials to G2 Shareholders has commenced, and the Meeting Materials are also available on the Company’s website at www.g2goldfields.com and under the Company’s profile on SEDAR+ at www.sedarplus.ca. The Arrangement On April 9, 2026, G2 entered into a definitive agreement with G Mining Ventures Corp. (“GMIN”) and G3 Goldfields Inc. (“G3”) pursuant to which GMIN will acquire all of the common shares of G2...

Continue reading

PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario

Purchase price of approximately $8.2 million The acquisition represents a continued expansion of PharmaCorp’s footprint in OntarioSASKATOON, Saskatchewan, May 25, 2026 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, today announced that it has entered into a definitive share purchase agreement, dated May 22, 2026 (the “Agreement”) to acquire from an arm’s length vendor group a 100% interest in a PharmaChoice Canada bannered pharmacy located in Morrisburg, Ontario (the “Acquisition”). The Acquisition continues the expansion of the Corporation’s geographical footprint and operating scale. Further to PharmaCorp’s acquisition pipeline update announced in its press release dated April 30,...

Continue reading

Mission Produce and Calavo Growers Merger Obtains Mexican Antitrust Approval

Merger Closing Expected to Occur May 28, 2026, Subject to Satisfaction of Closing Conditions OXNARD, Calif., May 22, 2026 (GLOBE NEWSWIRE) — Mission Produce, Inc. (NASDAQ: AVO) (“Mission Produce”) and Calavo Growers, Inc. (NASDAQ: CVGW) (“Calavo”), today announced, in connection with Mission Produce’s pending acquisition of Calavo, that Mission Produce has obtained antitrust clearance from Mexico’s Federal Economic Competition Commission (Comisión Federal de Competencia Económica, or “COFECE”). This clearance satisfies the acquisition’s closing condition set forth in the previously announced merger agreement regarding the receipt of antitrust approval in Mexico. As such, subject to the continued satisfaction of all closing conditions, Mission Produce and Calavo currently expect that the transaction will close on May 28, 2026. About...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.